ProCE Banner Activity

RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Slideset Download

Download these slides from a CCO Live Webinar to get up to date on the latest clinical data informing optimal treatment of patients with RET fusion–positive NSCLC, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer, including guidance on testing for RET alterations and monitoring for and managing common adverse events with new-generation, selective RET inhibitors. 

Released: January 21, 2021

Expiration: January 20, 2022

No longer available for credit.
Begin Activity

Share

Faculty

Taofeek K. Owonikoko

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Taofeek K. Owonikoko, MD, PhD

Professor
Department of Hematology and Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia